Remodeling domain interfaces to enhance heterodimer formation
暂无分享,去创建一个
L. Presta | Zhen-ping Zhu | L G Presta | Z Zhu | P Carter | G Zapata | G. Zapata | P. Carter
[1] P. S. Kim,et al. Peptide ‘Velcro’: Design of a heterodimeric coiled coil , 1993, Current Biology.
[2] P. Carter,et al. Engineering linear F(ab')2 fragments for efficient production in Escherichia coli and enhanced antiproliferative activity. , 1995, Protein Engineering.
[3] L. Presta,et al. 'Knobs-into-holes' engineering of antibody CH3 domains for heavy chain heterodimerization. , 1996, Protein engineering.
[4] P. Carter,et al. Toward the production of bispecific antibody fragments for clinical applications. , 1995, Journal of hematotherapy.
[5] I. Pastan,et al. Engineering interchain disulfide bonds into conserved framework regions of Fv fragments: improved biochemical characteristics of recombinant immunotoxins containing disulfide-stabilized Fv. , 1994, Protein engineering.
[6] A. Fersht,et al. Effects of engineering complementary charged residues into the hydrophobic subunit interface of tyrosyl-tRNA synthetase. Appendix: Kinetic analysis of dimeric enzymes that reversibly dissociate into inactive subunits. , 1987, Biochemistry.
[7] T. N. Bhat,et al. Small rearrangements in structures of Fv and Fab fragments of antibody D 1.3 on antigen binding , 1990, Nature.
[8] I. Kuntz,et al. Engineering human immunodeficiency virus 1 protease heterodimers as macromolecular inhibitors of viral maturation. , 1996, Proceedings of the National Academy of Sciences of the United States of America.
[9] G. Winter,et al. Construction of heterodimer tyrosyl-tRNA synthetase shows tRNATyr interacts with both subunits. , 1986, Proceedings of the National Academy of Sciences of the United States of America.
[10] T Prospero,et al. "Diabodies": small bivalent and bispecific antibody fragments. , 1993, Proceedings of the National Academy of Sciences of the United States of America.
[11] H. K. Schachman,et al. Regeneration of active enzyme by formation of hybrids from inactive derivatives: implications for active sites shared between polypeptide chains of aspartate transcarbamoylase. , 1985, Proceedings of the National Academy of Sciences of the United States of America.
[12] A. Ullrich,et al. The extracellular domain of HER2/neu is a potential immunogen for active specific immunotherapy of breast cancer. , 1990, Journal of biological response modifiers.
[13] J. Ponder,et al. Tertiary templates for proteins. Use of packing criteria in the enumeration of allowed sequences for different structural classes. , 1987, Journal of molecular biology.
[14] R. Kelley,et al. Thermodynamic analysis of an antibody functional epitope. , 1993, Biochemistry.
[15] L. Presta,et al. Engineering a humanized bispecific F(ab')2 fragment for improved binding to T cells. , 1992, International journal of cancer. Supplement = Journal international du cancer. Supplement.
[16] Brad Snedecor,et al. High Level Escherichia coli Expression and Production of a Bivalent Humanized Antibody Fragment , 1992, Bio/Technology.
[17] P. Carter,et al. Identification of heavy chain residues in a humanized anti-CD3 antibody important for efficient antigen binding and T cell activation. , 1995, Journal of immunology.
[18] G. Winter,et al. A model of synthetase/transfer RNA interaction as deduced by protein engineering , 1986, Nature.
[19] I. Pastan,et al. A recombinant immunotoxin containing a disulfide-stabilized Fv fragment. , 1993, Proceedings of the National Academy of Sciences of the United States of America.
[20] I. Pastan,et al. Stabilization of the Fv fragments in recombinant immunotoxins by disulfide bonds engineered into conserved framework regions. , 1994, Biochemistry.
[21] H. K. Schachman,et al. Shared active sites in oligomeric enzymes: model studies with defective mutants of aspartate transcarbamoylase produced by site-directed mutagenesis. , 1987, Proceedings of the National Academy of Sciences of the United States of America.
[22] L. Presta,et al. X-ray structures of the antigen-binding domains from three variants of humanized anti-p185HER2 antibody 4D5 and comparison with molecular modeling. , 1993, Journal of molecular biology.
[23] Thomas A. Kunkel,et al. Rapid and efficient site-specific mutagenesis without phenotypic selection. , 1985, Proceedings of the National Academy of Sciences of the United States of America.
[24] L. Presta,et al. Development of a humanized disulfide-stabilized anti-p185HER2 Fv-beta-lactamase fusion protein for activation of a cephalosporin doxorubicin prodrug. , 1995, Cancer research.
[25] B. Snedecor,et al. High Level Secretion of a Humanized Bispecific Diabody from Escherichia coli , 1996, Bio/Technology.